

Usha Menon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4893672/publications.pdf>

Version: 2024-02-01

321
papers

22,993
citations

14655

66
h-index

10734

138
g-index

337
all docs

337
docs citations

337
times ranked

26702
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 110-118.	2.3	2
2	Adaptation of colorectal cancer screening tailored navigation content for American Indian communities and early results using the intervention. <i>Implementation Science Communications</i> , 2022, 3, 6.	2.2	6
3	Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. <i>EBioMedicine</i> , 2022, 75, 103802.	6.1	18
4	Cost-Effectiveness of Community-to-Clinic Tailored Navigation for Colorectal Cancer Screening in an Underserved Population: Economic Evaluation Alongside a Group-Randomized Trial. <i>American Journal of Health Promotion</i> , 2022, , 089011712110684.	1.7	1
5	Association of adult attachment with delays in accessing specialist care in women with ovarian cancer. <i>Journal of Psychosocial Oncology</i> , 2022, 40, 491-505.	1.2	0
6	Adapting a conceptual framework to engage diverse stakeholders in genomic/precision medicine research. <i>Health Expectations</i> , 2022, , .	2.6	7
7	Cancer Screening Among Rural and Urban Clinics During COVID-19: A Multistate Qualitative Study. <i>JCO Oncology Practice</i> , 2022, 18, e1045-e1055.	2.9	9
8	Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews. <i>Diagnostics</i> , 2022, 12, 1028.	2.6	3
9	Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP). <i>British Journal of Cancer</i> , 2022, 127, 844-854.	6.4	4
10	Metabolic profiles of socio-economic position: a multi-cohort analysis. <i>International Journal of Epidemiology</i> , 2021, 50, 768-782.	1.9	15
11	Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer. <i>Journal of Medical Genetics</i> , 2021, 58, 305-313.	3.2	26
12	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. <i>Journal of the National Cancer Institute</i> , 2021, 113, 301-308.	6.3	8
13	Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 286-291.	2.5	25
14	Communicating and Coaching in Spanish for Chronic Care. <i>Journal of Nursing Education</i> , 2021, 60, 34-37.	0.9	2
15	Surgical decision making in premenopausal <i>BRCA</i> carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study. <i>Journal of Medical Genetics</i> , 2021, , jmedgenet-2020-107501.	3.2	9
16	Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Cancers</i> , 2021, 13, 858.	3.7	6
17	UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. <i>Trials</i> , 2021, 22, 173.	1.6	4
18	Startup and implementation costs of a colorectal cancer screening tailored navigation research study. <i>Evaluation and Program Planning</i> , 2021, 85, 101907.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Feasibility and Acceptability of a Language Concordant Health Coaching Intervention Delivered by Nurses for Latinx With Type 2 Diabetes. <i>Worldviews on Evidence-Based Nursing</i> , 2021, 18, 210-216.	2.9	3
20	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. <i>Carcinogenesis</i> , 2021, 42, 785-793.	2.8	6
21	Communication Among Southeast Asian Mothers and Daughters About Cervical Cancer Prevention. <i>Nursing Research</i> , 2021, 70, S73-S83.	1.7	0
22	Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 2182-2193.	13.7	313
23	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021, 108, 1190-1203.	6.2	6
24	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	6.4	9
25	Challenges of Cognitive Interviewing in Sensitive Health Topic Research. <i>Nursing Research</i> , 2021, 70, 376-382.	1.7	6
26	Completeness and accuracy of national cancer and death registration for outcome ascertainment in trialsâ€”an ovarian cancer exemplar. <i>Trials</i> , 2021, 22, 88.	1.6	7
27	Efficacy of a Language-Concordant Health Coaching Intervention for Latinx with Diabetes. <i>Patient Education and Counseling</i> , 2021, , .	2.2	1
28	Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 56.e1-56.e17.	1.3	25
29	The Self-Efficacy to Communicate about Sex and Intimacy (SECSI) scale: psychometric assessment in women treated for cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 1449-1457.	2.2	6
30	Human epididymis protein 4 antigenâ€”autoantibody complexes complement cancer antigen 125 for detecting earlyâ€”stage ovarian cancer. <i>Cancer</i> , 2020, 126, 725-736.	4.1	21
31	Effects of a Community-to-Clinic Navigation Intervention on Colorectal Cancer Screening Among Underserved People. <i>Annals of Behavioral Medicine</i> , 2020, 54, 308-319.	2.9	14
32	Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. <i>Cancers</i> , 2020, 12, 1931.	3.7	18
33	Perceptions of Cervical Cancer and Screening Behavior among Cambodian and Lao Women in the United States: An Exploratory, Mixed-Methods Study. <i>Journal of Health Care for the Poor and Underserved</i> , 2020, 31, 889-908.	0.8	3
34	Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 caseâ€”control studies. <i>European Journal of Epidemiology</i> , 2020, 35, 1025-1042.	5.7	2
35	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
36	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. <i>Cancers</i> , 2020, 12, 1241.	3.7	19

#	ARTICLE	IF	CITATIONS
37	Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the –no screen™ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Gynecologic Oncology</i> , 2020, 158, 316-322.	1.4	29
38	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020, 10, 9688.	3.3	2
39	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	7.0	43
40	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , 2020, 123, 793-802.	6.4	35
41	Circulating Fatty Acids and Risk of Coronary Heart Disease and Stroke: Individual Participant Data Meta-Analysis in Up to 16,126 Participants. <i>Journal of the American Heart Association</i> , 2020, 9, e013131.	3.7	36
42	Ovarian cancer screening: Current status and future directions. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 65, 32-45.	2.8	68
43	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. <i>Gynecologic Oncology</i> , 2020, 158, 702-709.	1.4	15
44	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i> . <i>Journal of the National Cancer Institute</i> , 2020, 112, 1242-1250.	6.3	106
45	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32
46	Agreement between questionnaires and registry data on routes to diagnosis and milestone dates of the cancer diagnostic pathway. <i>Cancer Epidemiology</i> , 2020, 65, 101690.	1.9	10
47	Socioeconomic Status and Ovarian Cancer Stage at Diagnosis: A Study Nested Within UKCTOCS. <i>Diagnostics</i> , 2020, 10, 89.	2.6	5
48	Improved early detection of ovarian cancer using longitudinal multimarker models. <i>British Journal of Cancer</i> , 2020, 122, 847-856.	6.4	60
49	Approach to High Volume Enrollment in Clinical Research: Experiences from an All of Us Research Program Site. <i>Clinical and Translational Science</i> , 2020, 13, 685-692.	3.1	7
50	The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease. <i>BMC Gastroenterology</i> , 2020, 20, 104.	2.0	5
51	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019, 79, 505-517.	0.9	49
52	Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. <i>British Journal of Cancer</i> , 2019, 121, 483-489.	6.4	32
53	Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. <i>PLoS Medicine</i> , 2019, 16, e1002893.	8.4	78
54	Precision health research and implementation reviewed through the conNECT framework. <i>Nursing Outlook</i> , 2019, 67, 302-310.	2.6	10

#	ARTICLE	IF	CITATIONS
55	Measuring quality and outcomes of research collaborations: An integrative review. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 261-289.	0.6	22
56	The 14q32 maternally imprinted locus is a major source of longitudinally stable circulating microRNAs as measured by small RNA sequencing. <i>Scientific Reports</i> , 2019, 9, 15787.	3.3	7
57	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	5.2	28
58	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	3.3	5
59	Advanced-stage cancer and time to diagnosis: An International Cancer Benchmarking Partnership (ICBP) cross-sectional study. <i>European Journal of Cancer Care</i> , 2019, 28, e13100.	1.5	44
60	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. <i>Modern Pathology</i> , 2019, 32, 1834-1846.	5.5	54
61	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , 2019, 8, 2503-2513.	2.8	6
62	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	12.8	90
63	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. <i>Genetics in Medicine</i> , 2019, 21, 2390-2400.	2.4	153
64	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. <i>Cancer Prevention Research</i> , 2019, 12, 391-400.	1.5	17
65	Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP). <i>BMJ Open</i> , 2019, 9, e025895.	1.9	19
66	Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis. <i>Menopause</i> , 2019, 26, 1100-1009.	2.0	20
67	Application of the ConNECT Framework to Precision Health and Health Disparities. <i>Nursing Research</i> , 2019, 68, 99-109.	1.7	14
68	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	6.2	711
69	Colorectal cancer ascertainment through cancer registries, hospital episode statistics, and self-reporting compared to confirmation by clinician: A cohort study nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Cancer Epidemiology</i> , 2019, 58, 167-174.	1.9	7
70	A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants. <i>International Journal of Cancer</i> , 2019, 144, 2192-2205.	5.1	12
71	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	3.0	22
72	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129.	6.4	15

#	ARTICLE	IF	CITATIONS
73	Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population. <i>Journal of Medical Genetics</i> , 2018, 55, 538-545.	3.2	45
74	Ovarian Cancer Prevention and Screening. <i>Obstetrics and Gynecology</i> , 2018, 131, 909-927.	2.4	176
75	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. <i>Journal of the National Cancer Institute</i> , 2018, 110, 714-725.	6.3	138
76	Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 431.e1-431.e12.	1.3	32
77	Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 34-42.	2.5	23
78	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2018, 47, 450-459.	1.9	15
79	Culturally Relevant Human Subjects Protection Training: A Case Study in Community-Engaged Research in the United States. <i>Journal of Immigrant and Minority Health</i> , 2018, 20, 107-114.	1.6	9
80	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. <i>American Journal of Epidemiology</i> , 2018, 187, 366-377.	3.4	8
81	Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP). <i>BMJ Open</i> , 2018, 8, e023870.	1.9	43
82	Rural-Urban Disparities in Time to Diagnosis and Treatment for Colorectal and Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1036-1046.	2.5	54
83	A quantitative performance study of two automatic methods for the diagnosis of ovarian cancer. <i>Biomedical Signal Processing and Control</i> , 2018, 46, 86-93.	5.7	16
84	Steps towards effective gynaecological cancer screening. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 538-540.	27.6	1
85	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. <i>Journal of Medical Genetics</i> , 2018, 55, 546-554.	3.2	38
86	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 250-261.	3.0	70
87	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561.	2.5	9
88	Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. <i>Clinical Cancer Research</i> , 2018, 24, 4726-4733.	7.0	39
89	Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis. <i>Oncotarget</i> , 2018, 9, 17430-17442.	1.8	23
90	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	4.1	3

#	ARTICLE	IF	CITATIONS
91	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	21.4	184
92	Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>F1000Research</i> , 2018, 7, 1241.	1.6	2
93	Parentclitic networks for predicting ovarian cancer. <i>Oncotarget</i> , 2018, 9, 22717-22726.	1.8	28
94	Dietary Profiles of First-Generation South Asian Indian Adolescents in the United States. <i>Journal of Immigrant and Minority Health</i> , 2017, 19, 309-317.	1.6	8
95	Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. <i>British Journal of Cancer</i> , 2017, 116, 501-508.	6.4	86
96	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. <i>British Journal of Cancer</i> , 2017, 116, 524-535.	6.4	23
97	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. <i>International Journal of Cancer</i> , 2017, 140, 2422-2435.	5.1	25
98	Randomized controlled dissemination study of community-to-clinic navigation to promote CRC screening: Study design and implications. <i>Contemporary Clinical Trials</i> , 2017, 53, 106-114.	1.8	4
99	Causal Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 135, 2373-2388.	1.6	304
100	The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT. <i>British Journal of Cancer</i> , 2017, 116, 1111-1117.	6.4	8
101	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
102	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. <i>British Journal of Cancer</i> , 2017, 116, 1223-1228.	6.4	13
103	Change-point of multiple biomarkers in women with ovarian cancer. <i>Biomedical Signal Processing and Control</i> , 2017, 33, 169-177.	5.7	13
104	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
105	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	27.8	1,099
106	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1470-1473.	2.5	10
107	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 338-340.	0.4	1
108	The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>British Journal of Cancer</i> , 2017, 117, 619-627.	6.4	29

#	ARTICLE	IF	CITATIONS
109	Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5912-5922.	7.0	47
110	Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2017, 7, e011822.	1.9	8
111	Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 578.e1-578.e12.	1.3	63
112	Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , 2017, 17, 603.	2.9	11
113	A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. <i>British Journal of Cancer</i> , 2017, 117, 666-674.	6.4	47
114	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424.	2.5	3
115	Metabolic Profiling of Adiponectin Levels in Adults. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	26
116	Methylation patterns in serum DNA for early identification of disseminated breast cancer. <i>Genome Medicine</i> , 2017, 9, 115.	8.2	49
117	Influences on anticipated time to ovarian cancer symptom presentation in women at increased risk compared to population risk of ovarian cancer. <i>BMC Cancer</i> , 2017, 17, 814.	2.6	5
118	The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. <i>Genome Medicine</i> , 2017, 9, 116.	8.2	122
119	Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2670.	4.1	23
120	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1411-1420.	1.6	148
121	Novel risk models for early detection and screening of ovarian cancer. <i>Oncotarget</i> , 2017, 8, 785-797.	1.8	13
122	Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. <i>Oncotarget</i> , 2017, 8, 3811-3825.	1.8	45
123	Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. <i>Oncotarget</i> , 2017, 8, 50930-50940.	1.8	43
124	The double-edged sword of ovarian cancer information for women at increased risk who have previously taken part in screening. <i>Ecanermedicalscience</i> , 2016, 10, 650.	1.1	0
125	Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>PLoS ONE</i> , 2016, 11, e0165539.	2.5	8
126	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.	1.9	71

#	ARTICLE	IF	CITATIONS
127	Ovarian cancer screening: UKCTOCS trial – Authors' reply. <i>Lancet</i> , The, 2016, 387, 2603-2604.	13.7	14
128	Should Opportunistic Bilateral Salpingectomy (OBS) for Prevention of Ovarian Cancer Be Incorporated Into Routine Care or Offered in the Context of a Clinical Trial?. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 31-33.	2.5	7
129	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. <i>Obstetrics and Gynecology</i> , 2016, 127, 828-836.	2.4	39
130	Factors Affecting Short-term Mortality in Women With Ovarian, Tubal, or Primary Peritoneal Cancer: Population-Based Cohort Analysis of English National Cancer Registration Data. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 56-65.	2.5	14
131	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. <i>Human Molecular Genetics</i> , 2016, 25, 3600-3612.	2.9	17
132	Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. <i>Journal of Medical Genetics</i> , 2016, 53, 472-480.	3.2	42
133	Specifying the ovarian cancer risk threshold of –premenopausal risk-reducing salpingo-oophorectomy™ for ovarian cancer prevention: a cost-effectiveness analysis. <i>Journal of Medical Genetics</i> , 2016, 53, 591-599.	3.2	57
134	Refining Ovarian Cancer Test accuracy Scores (ROCKETS): protocol for a prospective longitudinal test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer. <i>BMJ Open</i> , 2016, 6, e010333.	1.9	16
135	Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution. <i>Nature Communications</i> , 2016, 7, 11620.	12.8	56
136	Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS). <i>Steroids</i> , 2016, 110, 62-69.	1.8	16
137	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	3.8	19
138	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	1.9	111
139	Protein Z: A putative novel biomarker for early detection of ovarian cancer. <i>International Journal of Cancer</i> , 2016, 138, 2984-2992.	5.1	41
140	A splicing variant of <i>TERT</i> identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. <i>International Journal of Cancer</i> , 2016, 139, 2646-2654.	5.1	7
141	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	9.4	157
142	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
143	An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation. <i>BMJ Open</i> , 2016, 6, e009641.	1.9	33
144	Ovarian Cancer Screening and Mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 346-348.	0.4	3

#	ARTICLE	IF	CITATIONS
145	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 470-471.	0.4	0
146	Opportunistic bilateral salpingectomy (OBS) for the prevention of ovarian cancer should be offered in the context of a clinical trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 463-463.	2.3	10
147	Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 945-956.	13.7	791
148	Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 201-202.	1.6	0
149	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 780-790.	2.5	10
150	Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv347.	6.3	43
151	Importance of serial CA125 measurements over an absolute cutoff value for the detection of asymptomatic ovarian cancer in high-risk patients. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 133, 239-240.	2.3	2
152	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. <i>Cancer Epidemiology</i> , 2016, 41, 71-79.	1.9	20
153	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 446-454.	2.5	9
154	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. <i>Clinical Cancer Research</i> , 2016, 22, 1734-1743.	7.0	69
155	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv315.	6.3	77
156	Evidence of a genetic link between endometriosis and ovarian cancer. <i>Fertility and Sterility</i> , 2016, 105, 35-43.e10.	1.0	37
157	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
158	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	1.8	5
159	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	1.8	13
160	Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF- κ B Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. <i>EBioMedicine</i> , 2015, 2, 1331-1339.	6.1	49
161	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697.	1.3	22
162	Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	22

#	ARTICLE	IF	CITATIONS
163	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
164	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	2.9	40
165	Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening. International Journal of Gynecological Cancer, 2015, 25, 1519-1525.	2.5	10
166	Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection. Clinical Cancer Research, 2015, 21, 622-631.	7.0	158
167	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
168	Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial. Journal of the National Cancer Institute, 2015, 107, 379.	6.3	146
169	Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History-Based Testing. Journal of the National Cancer Institute, 2015, 107, 380.	6.3	135
170	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
171	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	7.0	33
172	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
173	Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health, 2015, 15, 253.	2.9	9
174	Screening for Gynaecological Cancers. , 2015, , 267-281.		0
175	Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Journal of Clinical Oncology, 2015, 33, 2062-2071.	1.6	166
176	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. Molecular Cancer Therapeutics, 2015, 14, 1495-1503.	4.1	26
177	Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy. Menopause, 2015, 22, 384-390.	2.0	25
178	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
179	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
180	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	28.4	839

#	ARTICLE	IF	CITATIONS
181	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	2.9	68
182	Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women. <i>Gynecologic Oncology</i> , 2015, 139, 487-494.	1.4	39
183	Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK. <i>Familial Cancer</i> , 2015, 14, 521-530.	1.9	14
184	Contribution of Germline Mutations in the <i>RAD51B</i> , <i>RAD51C</i> , and <i>RAD51D</i> Genes to Ovarian Cancer in the Population. <i>Journal of Clinical Oncology</i> , 2015, 33, 2901-2907.	1.6	266
185	Germline Mutations in the <i>BRIP1</i> , <i>BARD1</i> , <i>PALB2</i> , and <i>NBN</i> Genes in Women With Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	311
186	Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 671-676.	2.5	82
187	Multiprobabilistic prediction in early medical diagnoses. <i>Annals of Mathematics and Artificial Intelligence</i> , 2015, 74, 203-222.	1.3	9
188	Identifying hopelessness in population research: a validation study of two brief measures of hopelessness. <i>BMJ Open</i> , 2014, 4, e005093.	1.9	29
189	Mixed methods evaluation of well-being benefits derived from a heritage-in-health intervention with hospital patients. <i>Arts and Health</i> , 2014, 6, 24-58.	1.6	25
190	Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2014, 4, e004421.	1.9	15
191	Variation in NF- κ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1421-1427.	2.5	13
192	Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2014, 4, e005400-e005400.	1.9	8
193	Cancer-associated autoantibodies to MUC1 and MUC4: A blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. <i>International Journal of Cancer</i> , 2014, 134, 2180-2188.	5.1	49
194	Risk of Ovarian Cancer and the NF- κ B Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> . <i>Cancer Research</i> , 2014, 74, 852-861.	0.9	48
195	Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. <i>Cancer Immunology Research</i> , 2014, 2, 332-340.	3.4	21
196	A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. <i>Genome Medicine</i> , 2014, 6, 47.	8.2	53
197	Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 35-39.	2.3	7
198	The Effect of a Couples Intervention to Increase Breast Cancer Screening Among Korean Americans. <i>Oncology Nursing Forum</i> , 2014, 41, E185-E193.	1.2	38

#	ARTICLE	IF	CITATIONS
199	Ovarian cancer screeningâ€”Current status, future directions. <i>Gynecologic Oncology</i> , 2014, 132, 490-495.	1.4	115
200	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , 2014, 133, 481-497.	3.8	23
201	Adapting the coping in deliberation (CODE) framework: A multi-method approach in the context of familial ovarian cancer risk management. <i>Patient Education and Counseling</i> , 2014, 97, 200-210.	2.2	5
202	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt431-djt431.	6.3	186
203	Consortium analysis of gene and geneâ€”folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 2023-2035.	3.3	16
204	Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. <i>Proteomics - Clinical Applications</i> , 2014, 8, 982-993.	1.6	41
205	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , The, 2013, 14, 853-862.	10.7	335
206	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	21.4	326
207	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
208	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 caseâ€”control studies. <i>Cancer Causes and Control</i> , 2013, 24, 989-1004.	1.8	84
209	There is a need for routine peritoneal cytology at RRSO. <i>Gynecologic Oncology</i> , 2013, 128, 149-150.	1.4	1
210	The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. <i>Lancet Oncology</i> , The, 2013, 14, 1226-1232.	10.7	98
211	Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer. <i>Journal of Proteome Research</i> , 2013, 12, 1408-1418.	3.7	96
212	Ovarian cancer symptom awareness and anticipated time to help-seeking for symptoms among UK women. <i>Journal of Family Planning and Reproductive Health Care</i> , 2013, 39, 163-171.	0.8	43
213	Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 472-477.	1.7	14
214	Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule. <i>Journal of Clinical Oncology</i> , 2013, 31, 49-57.	1.6	126
215	Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1677-1686.	2.5	70
216	Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 880-890.	2.5	54

#	ARTICLE	IF	CITATIONS
217	Heritage, health and well-being: assessing the impact of a heritage focused intervention on health and well-being. <i>International Journal of Heritage Studies</i> , 2013, 19, 229-242.	1.9	44
218	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. <i>Endocrine-Related Cancer</i> , 2013, 20, 251-262.	3.1	169
219	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144
220	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 987-992.	2.5	20
221	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013, 4, 1627.	12.8	98
222	Screening for gynecological cancers. <i>Expert Review of Obstetrics and Gynecology</i> , 2013, 8, 143-160.	0.4	1
223	Using Museum Objects to Improve Wellbeing in Mental Health Service Users and Neurological Rehabilitation Clients. <i>British Journal of Occupational Therapy</i> , 2013, 76, 208-216.	0.9	26
224	Gene Set Analysis of Survival Following Ovarian Cancer Implicates Macrolide Binding and Intracellular Signaling Genes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 529-536.	2.5	7
225	Breast and Cervical Cancer Screening Among South Asian Immigrants in the United States. <i>Cancer Nursing</i> , 2012, 35, 278-287.	1.5	33
226	Predictive Value of Symptoms for Ovarian Cancer: Comparison of Symptoms Reported by Questionnaire, Interview, and General Practitioner Notes. <i>Journal of the National Cancer Institute</i> , 2012, 104, 114-124.	6.3	49
227	Quantitative evidence for wellbeing benefits from a heritage-in-health intervention with hospital patients. <i>International Journal of Art Therapy: Inscape</i> , 2012, 17, 63-79.	1.6	23
228	Ovarian cancer screening has no effect on disease-specific mortality. <i>Evidence-Based Medicine</i> , 2012, 17, 47-48.	0.6	7
229	Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. <i>Endocrine-Related Cancer</i> , 2012, 19, 137-147.	3.1	36
230	Genome-Wide Association Study for Ovarian Cancer Susceptibility Using Pooled DNA. <i>Twin Research and Human Genetics</i> , 2012, 15, 615-623.	0.6	8
231	Investigating the therapeutic potential of a heritage-object focused intervention: a qualitative study. <i>Journal of Health Psychology</i> , 2012, 17, 809-820.	2.3	20
232	Ovarian and cervical cancer awareness: development of two validated measurement tools. <i>Journal of Family Planning and Reproductive Health Care</i> , 2012, 38, 167-174.	0.8	52
233	International Conference on Ovarian Cancer Screening. <i>International Journal of Gynecological Cancer</i> , 2012, 22, S1.	2.5	3
234	The UKCTOCS Experience—Reasons for Hope?. <i>International Journal of Gynecological Cancer</i> , 2012, 22, S18-S20.	2.5	20

#	ARTICLE	IF	CITATIONS
235	Diathermy-Induced Injury May Affect Detection of Occult Tubal Lesions at Risk-Reducing Salpingo-Oophorectomy. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 881-888.	2.5	7
236	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. <i>Lancet Oncology</i> , The, 2012, 13, 385-394.	10.7	753
237	Screening of symptomatic women for ovarian cancer. <i>Lancet Oncology</i> , The, 2012, 13, e138-e139.	10.7	4
238	Enhancing Cancer Patient Well-Being With a Nonpharmacological, Heritage-Focused Intervention. <i>Journal of Pain and Symptom Management</i> , 2012, 44, 731-740.	1.2	21
239	Psychological outcomes of familial ovarian cancer screening: No evidence of long-term harm. <i>Gynecologic Oncology</i> , 2012, 127, 556-563.	1.4	18
240	Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 1555-1562.	1.7	38
241	Conformal predictors in early diagnostics of ovarian and breast cancers. <i>Progress in Artificial Intelligence</i> , 2012, 1, 245-257.	2.4	14
242	Preimplantation Genetic Diagnosis for Hereditary Cancers. <i>Advances in Experimental Medicine and Biology</i> , 2012, 732, 103-113.	1.6	3
243	Screening for ovarian cancer in the general population. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 243-256.	2.8	41
244	Withdrawal from familial ovarian cancer screening for surgery: Findings from a psychological evaluation study (PsyFOCS). <i>Gynecologic Oncology</i> , 2012, 124, 158-163.	1.4	12
245	The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. <i>Gynecologic Oncology</i> , 2012, 124, 185-191.	1.4	24
246	Multiprobabilistic Venn Predictors with Logistic Regression. <i>International Federation for Information Processing</i> , 2012, , 224-233.	0.4	5
247	Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. <i>Trials</i> , 2011, 12, 61.	1.6	40
248	Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. <i>Fertility and Sterility</i> , 2011, 95, 40-45.	1.0	20
249	Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). <i>European Journal of Cancer</i> , 2011, 47, 183-190.	2.8	91
250	Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 525-530.	5.0	30
251	Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. <i>Lancet Oncology</i> , The, 2011, 12, 38-48.	10.7	176
252	Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. <i>PLoS ONE</i> , 2011, 6, e24987.	2.5	48

#	ARTICLE	IF	CITATIONS
253	Can Ovarian Cancer Screening Save Lives? The Question Remains Unanswered. <i>Obstetrics and Gynecology</i> , 2011, 118, 1209-1211.	2.4	13
254	Mathematical Models to Discriminate Between Benign and Malignant Adnexal Masses: Potential Diagnostic Improvement Using Ovarian HistoScanning. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 35-43.	2.5	8
255	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011, 11, 719-725.	28.4	1,084
256	A Randomized Trial Comparing the Effect of Two Phone-Based Interventions on Colorectal Cancer Screening Adherence. <i>Annals of Behavioral Medicine</i> , 2011, 42, 294-303.	2.9	60
257	Psychosocial risk profiles among black male veterans administration patients non-adherent with colorectal cancer screening. <i>Psycho-Oncology</i> , 2011, 20, 1151-1160.	2.3	5
258	Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: Pooled analysis in five studies within the Ovarian Cancer Association Consortium. <i>International Journal of Cancer</i> , 2011, 128, 936-943.	5.1	49
259	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2011, 128, 2063-2074.	5.1	54
260	The <i>Sine Qua Non</i> of Discovering Novel Biomarkers for Early Detection of Ovarian Cancer: Carefully Selected Preclinical Samples. <i>Cancer Prevention Research</i> , 2011, 4, 299-302.	1.5	15
261	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. <i>Human Molecular Genetics</i> , 2011, 20, 2263-2272.	2.9	22
262	Ovarian Cancer Screening and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1544.	7.4	22
263	Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1028-1031.	2.5	0
264	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. <i>Clinical Cancer Research</i> , 2011, 17, 3742-3750.	7.0	47
265	<i>LIN28B</i> Polymorphisms Influence Susceptibility to Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 3896-3903.	0.9	75
266	MicroRNA Processing and Binding Site Polymorphisms Are Not Replicated in the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1793-1797.	2.5	19
267	Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011, 6, e19642.	2.5	5
268	Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011, 6, e20703.	2.5	21
269	DNA methylation of polycomb group target genes in cores taken from breast cancer centre and periphery. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 345-355.	2.5	10
270	Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. <i>Gynecologic Oncology</i> , 2010, 119, 479-483.	1.4	26

#	ARTICLE	IF	CITATIONS
271	A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. <i>Proteomics</i> , 2010, 10, 3388-3392.	2.2	32
272	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. <i>Nature Genetics</i> , 2010, 42, 874-879.	21.4	321
273	Genetic Variation in <i>TYMS</i> in the One-Carbon Transfer Pathway Is Associated with Ovarian Carcinoma Types in the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1822-1830.	2.5	24
274	Peptides Generated Ex Vivo from Serum Proteins by Tumor-Specific Exopeptidases Are Not Useful Biomarkers in Ovarian Cancer. <i>Clinical Chemistry</i> , 2010, 56, 262-271.	3.2	31
275	Evaluation of Candidate Stromal Epithelial Cross-Talk Genes Identifies Association between Risk of Serous Ovarian Cancer and TERT, a Cancer Susceptibility "Hot-Spot". <i>PLoS Genetics</i> , 2010, 6, e1001016.	3.5	48
276	<i>ESR1/SYNE1</i> Polymorphism and Invasive Epithelial Ovarian Cancer Risk: An Ovarian Cancer Association Consortium Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 245-250.	2.5	75
277	Development of a Multimarker Assay for Early Detection of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2159-2166.	1.6	246
278	Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. <i>Genome Research</i> , 2010, 20, 440-446.	5.5	740
279	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. <i>Human Molecular Genetics</i> , 2009, 18, 2297-2304.	2.9	42
280	Ovarian cancer. <i>BMJ: British Medical Journal</i> , 2009, 339, b4650-b4650.	2.3	5
281	Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. <i>Human Molecular Genetics</i> , 2009, 18, 1869-1878.	2.9	17
282	HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. <i>International Journal of Cancer</i> , 2009, 125, 2214-2218.	5.1	59
283	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. <i>Nature Genetics</i> , 2009, 41, 996-1000.	21.4	276
284	Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Lancet Oncology</i> , The, 2009, 10, 327-340.	10.7	738
285	Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. <i>Current Opinion in Obstetrics and Gynecology</i> , 2009, 21, 31-38.	2.0	23
286	Sensitivity and Specificity of Multimodal and Ultrasound Screening for Ovarian Cancer, and Stage Distribution of Detected Cancers: Results of the Prevalence Screen of the United Kingdom Collaborative Trial of Ovarian Cancer Screening. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 592-593.	0.4	0
287	An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer. <i>PLoS ONE</i> , 2009, 4, e8274.	2.5	291
288	OSPACS: Ultrasound image management system. <i>Source Code for Biology and Medicine</i> , 2008, 3, 11.	1.7	2

#	ARTICLE	IF	CITATIONS
289	Consortium analysis of 7 candidate SNPs for ovarian cancer. International Journal of Cancer, 2008, 123, 380-388.	5.1	73
290	Gynaecological ultrasonography: expertise counts. Lancet Oncology, The, 2008, 9, 88-89.	10.7	2
291	Polymorphism in the <i>IL18</i> Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3567-3572.	2.5	18
292	Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. BMJ: British Medical Journal, 2008, 337, a2079-a2079.	2.3	128
293	Interactive, Culturally Sensitive Education on Colorectal Cancer Screening. Medical Care, 2008, 46, S44-S50.	2.4	23
294	Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A Proof of Principle Study. PLoS ONE, 2008, 3, e2656.	2.5	131
295	Preanalytic Influence of Sample Handling on SELDI-TOF Serum Protein Profiles. Clinical Chemistry, 2007, 53, 645-656.	3.2	131
296	Health Behaviors in Cancer Survivors. Oncology Nursing Forum, 2007, 34, 643-651.	1.2	102
297	Ovarian cancer: challenges of early detection. Nature Clinical Practice Oncology, 2007, 4, 498-499.	4.3	16
298	Health Belief Model Variables as Predictors of Progression in Stage of Mammography Adoption. American Journal of Health Promotion, 2007, 21, 255-261.	1.7	51
299	Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause, 2007, 14, 462-467.	2.0	36
300	Serum Peptide Profiling using MALDI Mass Spectrometry. Proteomics, 2007, 7, 77-89.	2.2	51
301	Circulating Methylated DNA: A New Generation of Tumor Markers: Fig. 1.. Clinical Cancer Research, 2006, 12, 7205-7208.	7.0	29
302	Ovarian Cancer Screening. , 2006, , 47-68.		1
303	Screening for Ovarian Cancer. Clinical Obstetrics and Gynecology, 2006, 49, 433-447.	1.1	69
304	The value of ovarian cancer screening. British Journal of Hospital Medicine (London, England: 2005), 2006, 67, 314-317.	0.5	1
305	Prospective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer. Journal of Clinical Oncology, 2005, 23, 7919-7926.	1.6	218
306	Epithelial ovarian cancer and induction of ovulation. Reviews in Gynaecological Practice, 2005, 5, 131-138.	0.1	4

#	ARTICLE	IF	CITATIONS
307	Ovarian cancer screening. Cmaj, 2004, 171, 323-324.	2.0	24
308	Progress and Challenges in Screening for Early Detection of Ovarian Cancer. Molecular and Cellular Proteomics, 2004, 3, 355-366.	3.8	375
309	Screening for ovarian cancer. Reviews in Gynaecological Practice, 2004, 4, 156-161.	0.1	3
310	Screening for ovarian cancer. Expert Review of Anticancer Therapy, 2003, 3, 55-62.	2.4	14
311	Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal Women. Journal of Clinical Oncology, 2003, 21, 206s-210.	1.6	219
312	CA125 and Other Tumor Markers in Screening and Monitoring of Ovarian Cancer. , 2003, , 193-200.		2
313	Ovarian cancer screening. British Journal of Hospital Medicine, 2002, 63, 210-213.	0.2	10
314	Screening for ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 469-482.	2.8	43
315	Ovarian cancer screening in the general population. Current Opinion in Obstetrics and Gynecology, 2001, 13, 61-64.	2.0	36
316	Recent developments in ovarian cancer screening. Current Opinion in Obstetrics and Gynecology, 2000, 12, 39-42.	2.0	95
317	Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 1069-1074.	2.3	33
318	Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 165-169.	2.3	64
319	Ovarian cancer screening in the general population. Ultrasound in Obstetrics and Gynecology, 2000, 15, 350-353.	1.7	26
320	Screening for ovarian cancer: a pilot randomised controlled trial. Lancet, The, 1999, 353, 1207-1210.	13.7	545
321	Enhanced Liver Fibrosis Test Predicts Liver-Related Outcomes in Postmenopausal Women with Risk Factors - A Case Control Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). SSRN Electronic Journal, 0, , .	0.4	0